Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
RIC may leads to higher adverse events associated with RIC treatment compared with non‐RIC (low certainty).
It is very uncertain whether comparison 3: anticonvulsant levetiracetam changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 4: antipsychotics changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 5: benzodiazepines changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 1: 5HT1A partial agonists changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 8: NARIs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 9: NaSSAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 10: RIMAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
Comparison 12: SNRIs probably leads to higher dropouts due to adverse events (acute phase) compared with placebo (moderate certainty).
It is very uncertain whether comparison 2: anticonvulsants/GABAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
Comparison 13: SSRIs may leads to higher dropouts due to adverse events (acute phase) compared with placebo (low certainty).
Comparison 14: GW876008 showed no clear difference in dropouts due to adverse events (acute phase) compared with placebo (low certainty).
Rituximab (B cell) + steroid probably leads to higher treatment adverse events: UTI/pyelonephritis compared with steroid alone (moderate certainty).
The review found no eligible studies for this question.